HealthSWEDE: costs with sublingual immunotherapy—a Swedish questionnaire study

Abstract Background The aim of this cross-sectional survey was to compare the health-economic consequences for allergic rhinitis (AR) patients treated with sublingual Immunotherapy (SLIT) in terms direct and indirect costs a reference population receiving standard care pharmacological therapy. Methods Primary objective analyse SLIT grass pollen allergy Sweden vs group waiting subcutaneous immunotherapy (SCIT). A questionnaire mailed two groups AR patients. Results distributed 548 patients, 307 241 (waiting SCIT). Response rate 53.8%. Mean annual were higher than group; € 3907 (SD 4268) 2084 1623) p < 0.001. cost SLIT-patients, 1191 465) reference, 751 589) combined absenteeism presenteeism lower SLIT, 912 1530), 3346 4120) 0.001, as main driver. Conclusions seems be cost-beneficial way treat seasonal AR. This information might used guide future recommendations.